Aradigm (ARDM) PT Raised to $10 at Ladenburg Thalmann
Ladenburg Thalmann analyst Matthew Kaplan raised his price target on Aradigm (NASDAQ: ARDM) to $10.00 (from $7.50) while maintaining a Buy rating as FDA accepts Linhaliq NDA with priority review.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.